Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Phase 2

Completed

• Conditions: Renal Cell Carcinoma, Metastatic
• Interventions: Drug: Sunitinib

• Registration Number: NCT02432846
• Lead Sponsor: Mendus

Brief Summary

The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib post-nephrectomy vs Sunitinib post-nephrectomy patients.

Detailed Description

Patients, all planned for nephrectomy, will be stratified according to the Heng risk criteria (high risk patients vs. intermediate risk patients) and randomized in a 2:1 ratio to receive Intuvax (INN: ilixadencel)+ Sunitinib or Sunitinib alone.

Two doses of Intuvax (INN: ilixadencel) will be administered in to the primary tumour before nephrectomy. The control group will be scheduled for nephrectomy directly.

All patients will start Sunitinib treatment 5-8 weeks after operation.

Results from the phase I study, together with the results reported in the literature on the use of autologous dendritic cells (DCs) in combination with Sunitinib encourage Immunicum aktiebolag (AB) to further investigate the possibility of exploiting Intuvax (INN: ilixadencel) 10 million cells/dose when combined with Sunitinib for the treatment of mRCC patients.

Study Timeline

• Study Start: 2015-04
• Study First Submitted: 2015-04-15
• Study First Submitted QC: 2015-04-28
• Study First Posted: 2015-05-04
• Primary Completion: 2021-01-31
• Study Completion: 2021-01-31
• Results First Submitted: 2022-04-21
• Status Verified: 2022-07
• Results First Submitted QC: 2022-07-23
• Last Update Submitted: 2022-07-23
• Results First Posted: 2022-08-22
• Last Update Posted: 2022-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

1. Newly (<6 months) diagnosed RCC (histological/cytological verification is optional) with at least one (1) CT-verified metastasis ≥10mm for which complete metastasectomy is not planned. US patients must have verified clear-cell tumor histology

2. Planned resection of primary tumor

3. Primary tumor diameter ≥40 mm

4. Candidate for first-line therapy with sunitinib initiated 5-8 weeks after nephrectomy

5. Female or male ≥18 years of age

6. Willing and able to provide informed consent

7. Adequate hematological parameters, i.e:

   • B-Leukocyte count ≥4.5 x10e9/L
   • B-Platelet count ≥150 x10e9/L
   • B-Hemoglobin ≥90 g/L

8. S-creatinine and S-bilirubin ≤ 1.5 x upper limit of normal (ULN). Serum alanine aminotransferase (S-ALAT) and serum aspartate aminotransferase (S-ASAT) ≤ 2.5 x ULN (or ≤5 in case of liver metastases)

9. Female who has been post-menopausal for more than one (1) year or female of childbearing potential agreeing to use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner or combined birth control pills]) Female of childbearing potential must have a negative from Screening until 90 days after last dose of Intuvax and/or until completed sunitinib treatment whichever occurs later.blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax) and must not be lactating.

or Male agreeing to use condoms from Screening until 90 days after last dose of Intuvax and/or until completed sunitinib treatment whichever occurs later, or male having a female partner who is using a highly efficient method of contraception as described above.

Exclusion Criteria

1. Life expectancy less than 4 months

2. Central nervous system (CNS) metastasis that is symptomatic or progressing or untreated or that required current therapy (e.g. evidence of new or enlarging CNS metastasis or new neurological symptoms attributable to CNS metastases)

3. Active autoimmune disease which requires treatment with systemic immunosuppressive agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus (SLE), vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases

4. Treatment with per oral systemic corticosteroids exceeding 10mg/day within seven (7) days before Screening until nephrectomy (inhaled, intranasal and local steroids accepted irrespective of dose)

5. Known cardiomyopathy and/or clinical significant abnormal ECG findings at Screening disqualifying the patient from nephrectomy and from subsequent sunitinib treatment

6. Karnofsky performance status <70%

7. National Cancer Institute (NCI) Common Terminology criteria for Adverse Events (CTCAE) Grade 3 hemorrhage within 28 days before Screening

8. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication

9. Clinically significant gastrointestinal abnormalities

10. Uncontrolled hypertension, or uncontrolled diabetes mellitus

11. Pulmonary embolism within 12 months before screening

12. Prior history of invasive cancer within 5 years before screening, except for adequately treated in situ carcinomas or non-melanoma skin cancer

13. Ongoing infection that requires parenteral treatment with antibiotics

14. Active or latent virus disease (HIV, hepatitis B and hepatitis C)

15. Eastern Cooperative Oncology Group (ECOG) performance status >2 after optimization of analgesics

16. Abnormal and clinical significant coagulation parameters at the discretion of the Investigator, i.e.:

    • Prothrombin Time - International Normalized Ratio (PT-INR)
    • Activated Partial Thromboplastin Time (APTT) patients being treated with anticoagulants are excluded if the coagulation parameters are outside the therapeutic intervals as described in the summary of product characteristics (SmPC) / United States prescribing information (USPI) for the administered treatment

17. Known major adverse reaction/event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)

18. Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products

19. Prior systemic antitumour therapy within 28 days before Screening Visit. However, local radiation therapy to any area except for the abdominal/retroperitoneal area including the kidney tumour is allowed

20. Exposure to other investigational products within 28 days prior to Screening Visit

21. patients on anticoagulants for whom temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and or per local standard of care) during vaccination and nephrectomy, is not an option

22. History of alcohol or substance abuse

23. Any reason that, in the opinion of the Investigator, contraindicates that the patient participates in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib	Sunitinib	Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
Nephrectomy+Sunitinib	Sunitinib	Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).

Primary Outcome Measures

Name	Time	Method
18-Months' Overall Survival Percentage (PPS)	At 18 months (544 days)	The 18-month survival percentage was defined as the percentage of patients alive 18 months after randomization.
18-Months' Overall Survival Percentage (FAS)	At 18 months (544 days)	The 18-month survival percentage was defined as the percentage of patients alive 18 months after randomization.
Overall Survival (OS) - Days (FAS)	From the randomization to the date of death, up to 5 years after the last participant's 18-month survival data.	OS is the time from randomization until date of death. The patients who were alive at the end of study were followed for survival status (alive/date of death) through medical records, databases and public records according to the time frame below.; Due to censored data, estimates of upper 95% CI could not be determined in all reporting groups.
Overall Survival - Days (PPS)	From the randomization to the date of death, up to 5 years after the last patient's 18-month survival data.	OS is the time from randomization until date of death. The patients who were alive at the end of study were followed for survival status (alive/date of death) through medical records, databases and public records according to the time frame below.; Due to censored data, upper 95% CI could not be determined in all reporting groups.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS) From Start of Sunitinib According to RECIST 1.1.	From Sunitinib-Start to progressive disease or death, up to 18 months.	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by radiographic assessment: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.; Due to the large amount of censored data, estimates of median and/or a 95% CI could not be reliably determined in all reporting groups.; Baseline data are reported for the safety data set (all patients randomized) whereas PFS is analyzed for the full analysis set (FAS). Two patients in the safety data set were not included in the FAS since they withdrew prior to start of treatment.
Objective Response Rate (ORR) From Start of Sunitinib Treatment and Duration of Response in Each Subgroup.	From start of sunitinib treatment up to 18 months	Objective response rate was defined as the percentage of patients with complete response (CR) and partial response (PR).Tumor response was evaluated centrally according to the RECIST 1.1 guideline.
Number of Participants With Specific Best Overall Response	From start of sunitinib treatment up to 18 months	The best overall response is the best response recorded from the start of the treatment sunitinib until disease progression/recurrence; taking as reference for progressive disease (PD) the smallest measurements recorded since the treatment started. In general, the patient's best response assignment depended on the achievement of the measurement criteria.
Disease Control Rate	From start of sunitinib treatment up to 18 months	Best overall response (CR, PR or SD) evaluated from Sunitinib-Start for patients with available data.
Duration of Response	From first date of CR or PR until date of PD or death, up to 18 months.	The duration of response was calculated for only those patients who responded. It was the time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever came first).
Duration of Clinical Benefit	From first date of clinical benefit (CR, PR or SD) until date of PD or death, up to 18 months.	Disease control rate (DCR) also called Clinical Benefit Rate, was defined as the proportion of patients with CR or PR or SD.
Duration of Stable Disease	From first date of SD until PD or date of death, up to 18 months.	The duration of SD was calculated for only those patients who exhibited a best response of SD response as per RECIST v1.1. It was the time from first SD response to first observed progression of disease or death if the death was due to disease progression (whichever came first), up to 18 months.
Time to Progression (TTP)	Time from Sunitinib-Start to date of either PD according to RECIST 1.1 or clinical progression as evaluated by the Investigator, up to 18 months.	Due to the large amount of censored data, estimate of upper 95% CI could not be reliably determined in all reporting groups.
Percentage of Tumor Area With Infiltrating Cluster of Differentiation 8+ (CD8+) T-cells	At resection of primary tumor.	Relative number of tumor-infiltrating CD8+ T-cells in the resected primary tumor compared to number of infiltrating CD8+ T-cells in available diagnostic pre-biopsy (sample from either primary tumor or metastasis), was not to be evaluated as described in the protocol due to missing pre-biopsy samples). Instead an automated and validated quantification of percentage of CD8+ tissue in delineated tumor area was made.

Trial Locations

Locations (28)

Military Institute of Medicine; 🇵🇱 Warsaw, Poland

Rush University; 🇺🇸 Chicago, Illinois, United States

University of Illinois; 🇺🇸 Chicago, Illinois, United States

University of Iowa; 🇺🇸 Iowa City, Iowa, United States

Duke Cancer Institute; 🇺🇸 Durham, North Carolina, United States

Centre Hospitalier Universitaire d'Angers; 🇫🇷 Angers Cedex 9, France

Centre Hospitalier Universitaire de Toulouse-Hôpital Rangueil; 🇫🇷 Toulouse, France

University Hospital Olomouc; 🇨🇿 Olomouc, Czechia

University of Debrecen; 🇭🇺 Debrecen, Hungary

Szent-Györgyi Albert Klinikai Központ; 🇭🇺 Szeged, Hungary

Pauls Stradins Clinical University Hospital; 🇱🇻 Riga, Latvia

Riga East Clinical University Hospital; 🇱🇻 Riga, Latvia

Mazowiecki Szpital Onkologiczny; 🇵🇱 Wieliszew, Poland

Niepubliczny Zakład Opieki Zdrowotnej Vesalius Sp. z o.o.; 🇵🇱 Kraków, Poland

Wojewodzki Szpital Specjalistyczny; 🇵🇱 Lublin, Poland

Hospital Universitari Germans Trias i Pujol; 🇪🇸 Badalona, Spain

Hospital Universitario Puerta de Hierro Majadahonda; 🇪🇸 Majadahonda, Spain

Hospital Clinic de Barcelona; 🇪🇸 Barcelona, Spain

Hospital de la Santa Creu i Sant Pau; 🇪🇸 Barcelona, Spain

Hospital Universitari Parc Tauli; 🇪🇸 Sabadell, Spain

Hospital Universitario 12 de Octubre; 🇪🇸 Madrid, Spain

Sahlgrenska University Hospital; 🇸🇪 Göteborg, Sweden

Karolinska University Hospital; 🇸🇪 Huddinge, Sweden

Umeå University Hospital; 🇸🇪 Umeå, Sweden

Uppsala University Hospital; 🇸🇪 Uppsala, Sweden

Royal Preston Hospital; 🇬🇧 Preston, United Kingdom

The Churchill Hospital; 🇬🇧 Oxford, United Kingdom

Health Partners Institute; 🇺🇸 Saint Paul, Minnesota, United States